← All diseases
Cancer
Multiple myeloma
Do you want to receive a message when there is new research about Multiple myeloma? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, above each publication appears one sentence explaining what was investigated — and you receive a notification as soon as there is new research about Multiple myeloma. View what Premium costs.
Publications and studies (2162)
- Constructing reassurance and alignment: a discursive study of nurse-patient communication in transplant preparation. (2026/07/31) ♡
- More options, more questions in the management of early relapsed and/or refractory multiple myeloma. (2026/07/31) ♡
- Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies. (2026/07/31) ♡
- STAT3 inhibition eradicates multiple myeloma stem-like cells and induces immunogenic cell death. (2026/07/31) ♡
- Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework. (2026/07/30) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies. (2026/07/30) ♡
- Improving engraftment in autologous hematopoietic stem cell transplantation: comparing pegfilgrastim with filgrastim in an outpatient setting. (2026/07/30) ♡
- [Who refer patients with multiple myeloma to hematology-oncology: A retrospective study at Hôtel-Dieu de France]. (2026/07/30) ♡
- Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma. (2026/07/30) ♡
- Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort. (2026/07/30) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation. (2026/07/30) ♡
- Cancer treatment-related cardiovascular toxicity according to the ESC definition in patients receiving CAR T-cell therapy. (2026/07/30) ♡
- A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry. (2026/07/29) ♡
- A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models. (2026/07/29) ♡
- SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma. (2026/07/29) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. De-escalation trials in multiple myeloma: past, present and future. (2026/07/29) ♡
- Hyperviscosity Syndrome, Hypercalcemia, and Acute Renal Failure as Initial Manifestations of Multiple Myeloma in an Octogenarian. (2026/07/29) ♡
- Discovery of molecular glue degrader for treatment of IMiDs-resistant multiple myeloma based on GLUT-mediated tumor targeting strategy. (2026/07/28) ♡
- The association between allostatic load and monoclonal gammopathy of undetermined significance (MGUS). (2026/07/27) ♡
- Real-World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey. (2026/07/25) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case of postoperative diabetes insipidus following cervical decompressive laminectomies. (2026/07/24) ♡
- AI-augmented MALDI-TOF MS screening reveals a high burden of undiagnosed monoclonal gammopathy in adult patients. (2026/07/24) ♡
- Correction: Multi-kingdom gut microbiota analysis identifies bacterial-viral association in multiple myeloma. (2026/07/23) ♡
- UAP1 as a prognostic biomarker regulating malignant biological functions in multiple myeloma cells. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mitochondrial transfer-mediated metabolic reprogramming and drug resistance in bone metastasis: mechanisms and therapeutic strategies. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Next-generation T cell engagers for cancer and autoimmune diseases. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Natural Taste Modulators and Microbiome-Aware Nutritional Support for Immunotherapy-Associated Dysgeusia: A Translational Perspective for Precision Supportive Cancer Care. (2026/07/22) ♡
- Risk factors and clinical impact of bone pain in patients with multiple myeloma - A prospective interdisciplinary study. (2026/07/21) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. HSCT and CAR-T: a power couple-but who serves whom? (2026/07/21) ♡
- Correction: Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience. (2026/07/21) ♡
- Burden of infections and preventive strategies in patients with relapsed/refractory multiple myeloma treated with bispecific antibodies. (2026/07/20) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Modified pulse-dose melphalan therapy for canine colorectal extramedullary plasmacytoma with suspected hepatic dissemination following surgical excision. (2026/07/20) ♡
- Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients. (2026/07/16) ♡
- Long-period grating optical fiber sensor for IgG-type monoclonal protein measurement. (2026/07/15) ♡
- Single-cell profiling uncovers extracellular vesicle-associated malignant plasma cell subpopulations driving multiple myeloma progression. (2026/07/15) ♡
- Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. (2026/07/14) ♡
- Heterogeneity and Evolution of 68Ga-Pentixafor PET/CT Signals in Extramedullary Multiple Myeloma. (2026/07/13) ♡
- Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival. (2026/07/11) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Beyond Negative Electrophoresis and Immunofixation: A Three-Case Series of Non-secretory Multiple Myeloma. (2026/07/10) ♡
- Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma. (2026/07/09) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care. (2026/07/09) ♡
- Signals in Peripheral Blood: Tracking Redox Status and DNA Damage Response During the Progression of Multiple Myeloma. (2026/07/08) ♡
- Geriatric nutritional risk index predicts 10-year survival in patients with multiple myeloma. (2026/07/06) ♡
- Functional motif detection via in silico ablation using AlphaGenome. (2026/07/03) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Multiple Myeloma and the Illusion of the Evidence Pyramid. (2026/07/02) ♡
- Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper. (2026/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Complete Response to Teclistamab in a Pentarefractory Elderly Patient with Multiple Myeloma: A Real-World Case Report from India. (2026/07/01) ♡
- Plasma Cell Morphology: Many Faces, One Essence. (2026/07/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives. (2026/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction. (2026/07/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.